Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.58 |
| ▸ | APOB | P04114 | 4/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | MTTP | P55157 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793985 | 0.90 | SMO (0.60) | SMOTRPV1APOBNR3C1MTTP | |
| SCHEMBL6489790 | 0.89 | TRPV1 (0.50) | SMOTRPV1APOBNR3C1MTTP | |
| SCHEMBL6788522 | 0.89 | SMO (0.59) | SMOTRPV1APOBMTTPLMNA | |
| SCHEMBL6801341 | 0.87 | SMO (0.61) | SMOTRPV1APOBNR3C1MTTP | |
| SCHEMBL6788368 | 0.87 | SMO (0.61) | SMOTRPV1APOBNR3C1MTTP | |
| SCHEMBL6795684 | 0.86 | SMO (0.65) | SMOTRPV1APOBMTTPALDH1A1 | |
| SCHEMBL7080649 | 0.86 | SMO (0.54) | SMOTRPV1NR3C1MTTPLMNA | |
| SCHEMBL7085677 | 0.86 | LMNA (0.45) | SMOTRPV1LMNA | |
| SCHEMBL6793205 | 0.86 | PTGS1 (0.47) | SMOTRPV1APOBMTTP | |
| SCHEMBL6793814 | 0.85 | SMO (0.59) | SMOTRPV1APOBNR3C1MTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885TRPV1 3714/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.